000000_Synthonics_ChyloCureBook_Rev031919

Non-confidential Summary of Chylobinoid's Effect ChyloCure is a small biotechnology company which has recently developed a novel hemp derived product called chylobinoid that has shown to be very safe, well-tolerated, and have potent medicinal properties. Chylobinoid consists of 75-85% magnesium-cannabidiolic acid (Mg-CBDa), approximately 5% cannabidiol (CBD), 5% other cannabinoids, and naturally occurring plant lipids. Because of its hydrophilic (water loving) nature, the drug can be easily administered via capsules rather than as an oral solution as with many CBD products (e.g. Epidiolex). CBDa binds strongly to the 5-HT 1A receptor (for treatment of anxiety and depression), inhibits GPR-55 (the so called “third cannabinoid receptor” for treatment pain and cancer), and selectively inhibits the COX-2 receptor (for treatment of inflammation). It is for these reasons and its greater oral bioavailability that CBDa has shown to be far more potent than CBD for the management of epilepsy, nausea and other neurological disorders. In the case of CBDa (the biologically active plant precursor of CBD), coordination of CBDa with magnesium during the extraction process to form Mg-CBDa appears to further increase the complexes’ amphiphilicity (enhanced solubility and lipophilicity) and improve its total oral bioavailability from around 8% as seen with conventional CBD to up to around 75-80%. Introduction to Epilepsy Management using Mg-CBDa by Dr. Michael Smith: In addition to CBDa’s known ability to reduce neuroinflammation and traverse the blood-brain barrier, its coordination with magnesium may synergistically enhance antagonism of excitatory NMDA receptors in the brain and further augment the complex’s unique anti-seizure profile. Synthonics has created a powerful, innovative and patentable anti-epilepsy drug which may be significantly safer and more efficacious than Epidiolex, other AED’s currently on the market and even those under development. Given preliminary clinical results it is our strong belief that there is huge potential in using Mg-CBDa for those afflicted by refractory epilepsy as well as treating patients with other related neurological disorders such as autism and Fragile X Syndrome. We have had preliminary discussions with the Epilepsy Therapy Screening Program (ETSP), a section of NINDS/NIH, to study Mg-CBDa in their animal models, but this work had been delayed due to regulatory issues associated with the testing of cannabinoid products in federal facilities. FDA approval of Epidiolex last summer and recent passage of the Farm Bill, however, have significantly improved the regulatory climate and the view of CBD and similar cannabinoid drugs. Over the last twelve months we’ve been administering Mg-CBDa to several patients with refractory epilepsy and a patient with ALS with very positive results (see testimonials below). We’ve also been able to affirm that the drug remains safe, efficacious, and not interactive with other AEDs despite titrating up the dose in all cases. One patient who’s been taking the drug since May of last year has demonstrated a remarkable seizure reduction of 73% without adverse effects. Additionally, several patients have been able to reduce the dose of their other AEDs without increasing seizure frequency or severity.